Logo image of CRGX

CARGO THERAPEUTICS INC (CRGX) Stock Fundamental Analysis

NASDAQ:CRGX - US14179K1016 - Common Stock

4.47 USD
-0.07 (-1.54%)
Last: 8/18/2025, 9:25:47 PM
4.47 USD
0 (0%)
After Hours: 8/18/2025, 9:25:47 PM
Fundamental Rating

3

Taking everything into account, CRGX scores 3 out of 10 in our fundamental rating. CRGX was compared to 542 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for CRGX as it has an excellent financial health rating, but there are worries on the profitability. CRGX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CRGX has reported negative net income.
CRGX had a negative operating cash flow in the past year.
CRGX Yearly Net Income VS EBIT VS OCF VS FCFCRGX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

CRGX has a worse Return On Assets (-85.76%) than 71.14% of its industry peers.
CRGX's Return On Equity of -93.30% is in line compared to the rest of the industry. CRGX outperforms 47.61% of its industry peers.
Industry RankSector Rank
ROA -85.76%
ROE -93.3%
ROIC N/A
ROA(3y)-154.01%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CRGX Yearly ROA, ROE, ROICCRGX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 1K 2K 3K

1.3 Margins

CRGX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CRGX Yearly Profit, Operating, Gross MarginsCRGX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

The number of shares outstanding for CRGX has been increased compared to 1 year ago.
CRGX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CRGX Yearly Shares OutstandingCRGX Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 10M 20M 30M 40M
CRGX Yearly Total Debt VS Total AssetsCRGX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

An Altman-Z score of 2.91 indicates that CRGX is not a great score, but indicates only limited risk for bankruptcy at the moment.
CRGX's Altman-Z score of 2.91 is fine compared to the rest of the industry. CRGX outperforms 71.69% of its industry peers.
CRGX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.91
ROIC/WACCN/A
WACCN/A
CRGX Yearly LT Debt VS Equity VS FCFCRGX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 100M -100M 200M 300M 400M

2.3 Liquidity

CRGX has a Current Ratio of 12.37. This indicates that CRGX is financially healthy and has no problem in meeting its short term obligations.
CRGX has a Current ratio of 12.37. This is amongst the best in the industry. CRGX outperforms 85.48% of its industry peers.
CRGX has a Quick Ratio of 12.37. This indicates that CRGX is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of CRGX (12.37) is better than 85.48% of its industry peers.
Industry RankSector Rank
Current Ratio 12.37
Quick Ratio 12.37
CRGX Yearly Current Assets VS Current LiabilitesCRGX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

1

3. Growth

3.1 Past

CRGX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 92.79%, which is quite impressive.
EPS 1Y (TTM)92.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1.96%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 5.88% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y21.22%
EPS Next 2Y13.77%
EPS Next 3Y12.68%
EPS Next 5Y5.88%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CRGX Yearly Revenue VS EstimatesCRGX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 200M 400M 600M
CRGX Yearly EPS VS EstimatesCRGX Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -5 -10 -15 -20

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CRGX. In the last year negative earnings were reported.
Also next year CRGX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CRGX Price Earnings VS Forward Price EarningsCRGX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRGX Per share dataCRGX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

A more expensive valuation may be justified as CRGX's earnings are expected to grow with 12.68% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.77%
EPS Next 3Y12.68%

More info and screens

0

5. Dividend

5.1 Amount

CRGX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CARGO THERAPEUTICS INC

NASDAQ:CRGX (8/18/2025, 9:25:47 PM)

After market: 4.47 0 (0%)

4.47

-0.07 (-1.54%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-06 2025-08-06/amc
Earnings (Next)11-10 2025-11-10
Inst Owners98.83%
Inst Owner Change1.91%
Ins Owners0.35%
Ins Owner Change7.92%
Market Cap216.17M
Analysts49.09
Price Target5.61 (25.5%)
Short Float %6.31%
Short Ratio1.57
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-35.97%
Min EPS beat(2)-65.12%
Max EPS beat(2)-6.83%
EPS beat(4)2
Avg EPS beat(4)-11.28%
Min EPS beat(4)-65.12%
Max EPS beat(4)23.75%
EPS beat(8)4
Avg EPS beat(8)-199.15%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.13%
PT rev (3m)-48.48%
EPS NQ rev (1m)-8.33%
EPS NQ rev (3m)-16.77%
EPS NY rev (1m)-2.34%
EPS NY rev (3m)-6.12%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.91
P/tB 0.91
EV/EBITDA N/A
EPS(TTM)-3.66
EYN/A
EPS(NY)-2.62
Fwd EYN/A
FCF(TTM)-3.97
FCFYN/A
OCF(TTM)-3.92
OCFYN/A
SpS0
BVpS4.92
TBVpS4.92
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -85.76%
ROE -93.3%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-154.01%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 28.26%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.37
Quick Ratio 12.37
Altman-Z 2.91
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)322.35%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)92.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1.96%
EPS Next Y21.22%
EPS Next 2Y13.77%
EPS Next 3Y12.68%
EPS Next 5Y5.88%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-0.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year25.28%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-266.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-288.58%
OCF growth 3YN/A
OCF growth 5YN/A